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Antimicrobial susceptibility was analyzed for 354 
typhoidal Salmonella	 isolates	 collected	during	1999–2012	
in the Netherlands. In 16.1% of all isolates and in 23.8% of 
all	 isolates	 that	 showed	 increased	MICs	 for	 ciprofloxacin,	
the MIC for azithromycin was increased. This resistance 
may complicate empirical treatment of enteric fever.
Enteric fever caused by Salmonella enterica serotypes Typhi and Paratyphi A, B, and C is mainly a disease 
of the developing world, and it is occasionally diagnosed 
as an imported disease in countries where the disease is 
not endemic (1). Its empirical treatment has been ham-
pered by resistance to ampicillin, chloramphenicol, and 
trimethoprim and by decreased ciprofloxacin susceptibil-
ity (MIC for ciprofloxacin 0.125–1.0 µg/mL), and cipro-
floxacin resistance (MIC for ciprofloxacin >1.0 µg/mL) 
(2,3). As a consequence, third-generation cephalosporins 
are used as first-line drugs for intravenous treatment, and 
azithromycin is frequently used for empirical treatment of 
uncomplicated enteric fever.
Although no clinical breakpoints are available to define 
azithromycin susceptibility or resistance, several clinical 
studies have demonstrated good efficacy of azithromycin 
for the treatment of uncomplicated enteric fever in clinical 
and in vitro studies (4–10). Regarding MIC breakpoints, 
the European Committee on Antimicrobial Susceptibility 
Testing states that isolates with an MIC <16 µg/mL for 
azithromycin should be considered as wild-type organisms 
that are responsive to treatment (3). The Clinical and Labo-
ratory Standards Institute (www.clsi.org/) does not provide 
clinical breakpoints for macrolides for the group of Entero-
bacteriaceae. In previous studies of typhoidal Salmonella 
isolates, MICs for azithromycin ranged from 4 µg/mL to 
64 µg/mL (8–13). 
The first clinical case for which treatment of illness 
caused by typhoidal Salmonella spp. with azithromycin 
(MIC 256 µg/mL) failed was reported during 2010, evi-
denced by testing a S. enterica Paratyphi A isolate from 
Pakistan (14). Further, in a study of isolates from blood 
samples collected in India during 2005–2008, MICs >16 
µg/mL for azithromycin were observed in 34.7% (35/101 
isolates) of the typhoidal Salmonella isolates; clinical non-
response was reported in 19 of 36 patients treated with 
azithromycin (13). Whether this problem of increasing 
MICs for azithromycin is limited to India or is emerging 
globally is not clear. The objective of our study was to in-
vestigate azithromycin susceptibility and trends in antibac-
terial drug resistance over time in isolates collected during 
1999–2012 in the Netherlands.
The Study
Enteric fever is a notifiable disease in the Netherlands. 
During January 1999–December 2012, a total of 354 iso-
lates were submitted by microbiology laboratories to the 
Salmonella National and Community Reference Labora-
tory (www.eurlsalmonella.eu/): 177 (50%) S. enterica Ty-
phi isolates, 98 (27.7%) S. enterica  Paratyphi A isolates, 
78 (22.0%) S. enterica  Paratyphi B isolates, and 1 (0.3%) 
S. enterica Paratyphi C isolate. There was no statistically 
significant difference in sex among patients whose tests 
showed S. enterica  Typhi isolates (56.3% male, 43.7% fe-
male, p = 0.18) and S. enterica  Paratyphi isolates (51.6% 
male, 48.4% female, p = 0.18). Patients ranged in age from 
0 to 92 years. The median ages, 28.4 and 29.5 years, re-
spectively (p = 0.60), did not differ between patients in 
whose samples S. enterica Typhi and Paratyphi were iso-
lated. Trends in cumulative 1-year incidence were deter-
mined by linear regression analysis; data were weighted on 
the number of isolates collected each year. The cumulative 
1-year incidence of enteric fever was relatively stable dur-
ing 1999–2012, with an average of 25 isolates (4–39/year) 
for that period (p = 0.42).
All MICs were determined by using the broth micro-
dilution method with Mueller-Hinton II cation–adjusted 
broth (Difco, Franklin Lakes, NJ, USA). We applied Eu-
ropean Committee for Antimicrobial Susceptibility Test-
ing guidelines for category interpretation for different 
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antibacterial drugs (3). Azithromycin MICs were 2–256 
µg/mL among the 354 isolates and were increased in 57 
(16.1%) of the isolates (Figure 1). The distribution of 
azithromycin MICs of S. enterica Typhi and Paratyphi A 
and B peaked at 8, 16, and 8 µg/mL, respectively (Figure 
1). Trend analysis showed no increased MIC over time for 
all isolates (p = 0.21) or for S. enterica Typhi (p = 0.35) 
or Paratyphi (p = 0.70). One Paratyphi A isolate, from a 
sample acquired in Malaysia in 2007, required an MIC of 
256 µg/mL. Decreased susceptibility to ciprofloxacin was 
observed in 116 (32.8%) and ciprofloxacin resistance in 6 
(1.7%) of the 354 isolates. Cumulative 1-year incidence of 
isolates with decreased susceptibility or resistance to cip-
rofloxacin increased significantly from 0% (0/12 isolates) 
in 1999 to 64.3% (18/28 isolates) in 2012 (p<0.001) (on-
line Technical Appendix Figure, wwwnc.cdc.gov/EID/
article/20/4/13-1536-Techapp1.pdf). Among isolates with 
decreased susceptibility or resistance to ciprofloxacin, 
23.8% (29/122 isolates) showed an increased MIC for 
azithromycin; MIC increased for 12.1% (28/232 isolates) 
of the ciprofloxacin-susceptible isolates (p = 0.004) (Figure 
2). No significant increase in amoxicillin, trimethoprim, or 
chloramphenicol resistance was observed (amoxicillin, p 
= 0.97; trimethoprim, p = 0.95; and chloramphenicol, p = 
0.99) (online Technical Appendix Figure). For all isolates, 
the MICs for erythromycin ranged from 64 to ≥512 µg/mL. 
Resistance to third-generation cephalosporins was not ob-
served in the isolates.
The origins of isolates for which the country of ac-
quisition was known (205 of 354 strains) were distrib-
uted among geographic regions by using the United Na-
tions geoscheme (http://unstats.un.org/unsd/methods/m49/
m49regin.htm). Besides imported cases from countries 
in which enteric fever is highly endemic, such as India, 
Indonesia, and Pakistan, rates of importation were high for 
travelers from Turkey and Morocco (Table).
Percentages of elevated MICs for azithromycin were 
highest for isolates acquired in regions that had concurrent 
high proportions of isolates with decreased susceptibility 
or resistance to ciprofloxacin (Table). In isolates acquired 
in countries from Southern Asia, increased MICs for cip-
rofloxacin and increased MICs for azithromycin  were ob-
served in 21.4% (18/84 isolates) of the isolates.
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Figure 1. MICs of azithromycin of 354 
Salmonella enterica serotypes Typhi 
and Paratyphi A, B, and C isolates 
from samples collected from ill 
returned travelers in the Netherlands, 
1999–2012.	 For	 wild	 type	 isolates,	
MIC<16 µg/mL.
Figure	 2.	 MICs	 of	 azithromycin	 in	 relation	 to	 ciprofloxacin	
susceptibility of 354 Salmonella enterica serotypes Typhi and 
Paratyphi isolates. Increased MICs for azithromycin (MIC >16 
µg/mL)	 in	 isolates	 with	 decreased	 ciprofloxacin susceptibility or 
ciprofloxacin	resistance	(MIC	>0.125 µg/mL)	versus	ciprofloxacin-
susceptible isolates (MIC <0.125 µg/mL)	(p	=	0.004).
Increased MICs for Azithromycin, the Netherlands
Conclusions
We found high percentages of elevated azithromy-
cin MICs in typhoidal Salmonella isolates collected in 
the Netherlands during 1999–2012. MICs >16 µg/mL for 
azithromycin were found in 16.1% of all isolates and in 
23.8% of isolates with elevated MICs for ciprofloxacin. 
This observation may be explained by increased use of 
azithromycin in countries from which samples yielded 
high rates of typhoidal Salmonella isolates with decreased 
susceptibility or resistance to ciprofloxacin. Moreover, our 
findings are aligned with an alarming report from India on 
increasing MICs for azithromycin (13). Our study shows 
higher MICs than anticipated based on another Western 
case series (11), implying that these potentially resistant 
strains are not confined to India.
Besides treatment with third-generation cephalospo-
rins, empirical treatment options may be scarce for patients 
with potential azithromycin-resistant Salmonella serotypes. 
Reuse of antibacterial drugs, such as ampicillin, chloram-
phenicol, or trimethoprim may be a valuable treatment op-
tion upon proven susceptibility, but widespread use of these 
antibacterial drugs as first-line treatment will likely result 
in rapid reemergence of multidrug resistance and associ-
ated drug-related adverse effects. Further, increasing the 
dose of ciprofloxacin or using alternative fluoroquinolones 
has been suggested as an effective treatment in some cases 
(15). This option will not be feasible for empirical treatment 
because it applies only in a minority of cases and may be 
associated with drug toxicity. The danger of losing azithro-
mycin to antimicrobial resistance could be detrimental in 
countries faced with endemic or epidemic enteric fever and 
complicated by poverty; therefore, azithromycin should be 
used with care. The results of this study also implicate the 
importance of developing more effective vaccines as con-
trol measures for enteric fever. Future research is needed to 
evaluate clinically relevant breakpoints of azithromycin by 
analyzing the treatment outcome of azithromycin in rela-
tion to their MICs.
In conclusion, typhoidal Salmonella isolates in ill re-
turned travelers from the Netherlands already show a high 
percentage of increased MICs for azithromycin. Because the 
highest proportions of increased MICs for azithromycin are 
found in isolates with increased MICs for ciprofloxacin and 
in regions where decreased susceptibility or resistance to 
ciprofloxacin is already widely prevalent among S. enterica 
Typhi and Paratyphi isolates, this resistance may further 
limit future treatment options for enteric fever.
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